The Firm is currently offering confidential Actos lawsuit evaluations to long-term users of Actos who have been diagnosed with bladder cancer.
(PRWeb August 31, 2013)
Read the full story at http://www.prweb.com/releases/actos-lawsuit/actos-bladder-cancer/prweb11079665.htm
Read the full article.Conference call webcast and slide presentation Tuesday, Sept. 3, 11:30 a.m. ET at www.isispharm.com
Isis Pharmaceuticals, Inc. (PRNewsFoto/Isis Pharmaceuticals, Inc.)
CARLSBAD, Calif., Aug. 31, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced interim data from an ongoing Phase 2 study of ISIS-APOCIIIRx as a monotherapy in patients with very high to severely high triglycerides. These data were presented today by Dr. Daniel Gaudet at a PACE session occurring concurrently with the European Society of Cardiology in Amsterdam. In this study, patients treated with ISIS-APOCIIIRx achieved statistically significant mean reductions of up to 79 percent in apolipoprotein C-III (apoC-III) and up to 75 percent in triglycerides. In addition, patients treated with ISIS-APOCIIIRx achieved statistically significant mean increases of up to 57 percent in high-density lipoprotein cholesterol (HDL-C), the 'good' cholesterol. Patients also achieved up to 89 percent mean reduction in apoC-III-associated very low-density lipoprotein (VLDL) particles.
(Logo: http://photos.prnewswire.com/prnh/20130807/LA60006LOGO)
"Patients with very high levels of triglycerides experience a significant number of health problems, including type 2 diabetes, obesity, cardiovascular disease and, for patients with severely elevated triglycerides, pancreatitis. For these patients, there are very limited treatment options and what is needed is a much more effective drug that can be used as a single agent or in combination with other triglyceride-lowering agents," said Daniel Gaudet, M.D., Ph.D., from the department of medicine, University of Montreal and scientific director, Genome Quebec Biobank Technology Center. "The comprehensive Phase 2 data reported this summer demonstrate that ISIS-APOCIIIRx has the potential to fill this need."
The monotherapy portion of the ongoing Phase 2 study of ISIS-APOCIIIRx is a double-blind, randomized, placebo-controlled 13-week study designed to assess the safety and activity of ISIS-APOCIIIRx in patients with very high to severely high triglyceride levels (between 440 and 2,000 mg/dL). The data reported today is an interim analysis of 28 patients who completed 13 weeks of treatment with ISIS-APOCIIIRx or placebo. In this study, patients treated with ISIS-APOCIIIRx experienced dose-dependent, robust and prolonged, mean percent reductions from baseline in apoC-III, triglycerides and apoC-III-associated VLDL particles. Furthermore, these patients demonstrated a rapid, prolonged and statistically significant mean percent increase from baseline in HDL-C.
Table 1: ISIS-APOCIIIRx Produced Statistically Significant Reductions of Triglycerides, ApoC-III and ApoC-III-associated VLDL as a Single Agent in a Phase 2 Study in Patients with Very High to Severely High Triglyceride Levels. Mean % Changes From Baseline at Primary Endpoint.*
| Placebo (n=9) | ISIS-APOCIIIRx 100 mg (n=9) | ISIS-APOCIIIRx 200 mg (n=5) | ISIS-APOCIIIRx 300 mg (n=5) | |
| ApoC-III | +5% | -43% (p=0.04) | -72% (p=0.004) | -79% (p=0.003) |
| Triglycerides | +26% | -31% (p=0.08) | -65% (p=0.02) | -75% (p=0.004) |
| ApoC-III VLDL | +19% | -27% (p=0.17) | -73% (p=0.003) | -89% (p=0.004) |
| HDL-C | +3% | +30% (p=0.08) | +51% (p=0.002) | +57% (p=0.001) |
| non-HDL | +17% | -8% (p=0.16) | -5% (p=0.36) | -39% (p=0.007) |
| P value = vs. placebo *Interim analysis | ||||
In the ongoing study, patients received 100 mg, 200 mg or 300 mg dose of ISIS-APOCIIIRx, or placebo via weekly subcutaneous injections. In this interim analysis, patients had an average fasting triglyceride level of 602 mg/dL with incoming triglyceride levels up to 1,822 mg/dL. In this study ISIS-APOCIIIRx was found to be generally safe and well tolerated. The most common adverse event (AE) was injection site reactions, which were infrequent, predominantly mild and typically resolved rapidly. There were no flu-like symptoms, no treatment-related elevations of liver enzymes greater than three times upper limit of normal, no abnormalities in renal function and no clinically meaningful changes in other laboratory values.
"We are pleased with the performance of ISIS-APOCIIIRx to date. We have now demonstrated that ISIS-APOCIIIRx is equally effective in patients with high to severely high triglycerides as well as in patients with high triglycerides and type 2 diabetes. We have demonstrated that ISIS-APOCIIIRx can work equally well as a single agent and in combination with fibrates to produce significant reductions in apoC-III and triglycerides, and increases in HDL-C. In addition, the positive effect of ISIS-APOCIIIRx treatment on lipid parameters, improvements in glucose control and trends toward improvements in insulin sensitivity, suggest that ISIS-APOCIIIRx could have a very attractive therapeutic profile for patients with severely high triglycerides, who often also have diabetes or metabolic syndrome," said Richard Geary, Ph.D., senior vice president of development at Isis. "We look forward to discussing our Phase 3 plans with regulators and moving rapidly into a Phase 3 program next year in patients with severely high triglycerides."
ISIS-APOCIIIRx is an antisense drug intended to treat patients with severely high triglycerides either as a single agent or in combination with other triglyceride-lowering agents. ISIS-APOCIIIRx targets apoC-III, a gene produced in the liver that plays a central role in the regulation of serum triglycerides. Humans who do not produce apoC-III have lower levels of triglycerides and lower instances of cardiovascular disease. In clinical studies, patients with lower levels of apoC-III and triglycerides exhibit lower cardiovascular event rates. Humans with elevated levels of apoC-III have increased dyslipidemia associated with multiple metabolic abnormalities, such as insulin resistance and/or metabolic syndrome. In addition, the prevalence of type 2 diabetes is increased in patients with elevated triglycerides.
Conference Call
At 11:30 a.m. Eastern Time Tuesday, Sept. 3, 2013, Isis will conduct a live webcast and slide presentation conference call to discuss the positive Phase 2 data presented today. Interested parties may listen to the call by dialing 866-652-5200, or access the webcast with or without audio at www.isispharm.com. A webcast replay will be available for a limited time at the same address.
ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners. Isis' broad pipeline consists of 29 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer. Isis' partner, Genzyme, is commercializing Isis' lead product, KYNAMRO™, in the United States for the treatment of patients with HoFH. Genzyme is also pursuing marketing approval of KYNAMRO in other markets. Isis' patents provide strong and extensive protection for its drugs and technology. Additional information about Isis is available at www.isispharm.com.
ISIS PHARMACEUTICALS' FORWARD-LOOKING STATEMENT
This press release includes forward-looking statements regarding the discovery, development, and potential of drugs for cardiovascular diseases, and the development, activity, therapeutic potential and safety of ISIS-APOCIIIRx. Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs, including the commercial potential of KYNAMRO, is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2012 and its most recent quarterly report on Form 10-Q, which are on file with the SEC. Copies of these and other documents are available from the Company.
Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, Inc. KYNAMRO™ is a trademark of Genzyme Corporation.
SOURCE Isis Pharmaceuticals, Inc.
RELATED LINKS
http://www.isispharm.com
Dr. Schaller of Naples, FL has been named a Patients' Choice Award Winner for 2012. (PRNewsFoto/American Registry)
NAPLES, Fla., Aug. 30, 2013 /PRNewswire-USNewswire/ -- Among the select few physicians honored with the prestigious Patients' Choice Award this year is Dr. James Schaller, MD, MAR.
(Photo: http://photos.prnewswire.com/prnh/20130830/DC72230)
In fact, of the nation's 870,000 active physicians and dentists, just five percent consistently received top scores from their patients on sites like Vitals (http://www.vitals.com), qualifying them for this honor in 2012.
Millions of patients go online each year to rate their doctors on various components of care, including accuracy of their diagnosis, the amount of time they spent with the doctor, and the doctor's bedside manner and follow-up care. Patients' Choice reviews these rankings and other quality measures to compile its yearly list of award winners.
Dr. James Schaller, MD, MAR commented on the recognition: "I'm so honored to receive an award that's based on how my patients view the quality of care I provide. I strive each day to exceed my patients' expectations, and I'm grateful that they've recognized my efforts."
About James Schaller, MD, MAR: a short profile by and about the honoree:
Dr. Schaller offers unique care to patients from all over the world who have failed the best physicians and alternative healers, who seek a full time reader/researcher who has no interest in position or merely talk about 20 genres of healing--he publishes in them. With 50 books and papers in medicine's top journals, Dr. Schaller has twenty more books on deck and a passion to help the helpless suffering from non-surgical non-cancer treatment failure. His current interests to help: tick infections, biofilm, severe fatigue, mystery illness, herbal/plant oil medicine, fibromyalgia and inflammation.
For more information on this Patients' Choice Award winner, please visit Dr. James Schaller, MD, MAR's profile on PatientsChoice.org.
Following the publication of James Schaller, MD, MAR's selection for the Patient's Choice Award, American Registry seconded the honor and added Dr. Schaller to The Registry™ of Business Excellence. An exclusive recognition plaque has been designed to commemorate the honor. The doctor's custom wall plaque is shown here.
For more information on Dr. James Schaller, MD, MAR, located in Naples, FL, please call 239-263-0133, or visit www.personalconsult.com.
This press release was written by American Registry, LLC with approval by and/or contributions from Dr. Schaller and was distributed by PR Newswire, a subsidiary of UBM plc.
Patients' Choice provides in-depth information on doctors in your area who have been recognized and awarded for outstanding patient care and expertise. The Patients' Choice Award is the honor roll of physicians who have received the highest ratings by their patients.
American Registry, LLC, recognizes excellence in top businesses and professionals. The Registry™ includes over 2 million significant business and professional recognitions. For more information, search The Registry at http://www.americanregistry.com.
Contact Info:
Dr. James Schaller, MD, MAR
Phone: 239-263-0133
Email Address: jameslschallermd@gmail.com
SOURCE American Registry
RELATED LINKS
http://www.americanregistry.com
The Worldwide Beauty and Fitness Organization (WBFF) hosted its 2013 World Championships at the Planet Hollywood Resort and Casino in Las Vegas, NV. Cellucor Athlete, Jen Jewell, won 2nd place in the...
(PRWeb August 30, 2013)
Read the full story at http://www.prweb.com/releases/2013/8/prweb11076951.htm
Lecturing people about taking their makeup off before bed is the average beauty editor’s favourite pastime (second only to hysterical evangelism about sunscreen). But don’t worry—this isn’t going to be a lecture. Instead, […]
The post Will sleeping with makeup on actually age your skin? appeared first on beautyeditor.
Lecturing people about taking their makeup off before bed is the average beauty editor’s favourite pastime (second only to hysterical evangelism about sunscreen).
But don’t worry—this isn’t going to be a lecture. Instead, I want to talk about some of the claims coming out of the latest Daily Mail sensationalist beauty piece, about how 40-year-old writer Anna Pursglove aged herself by an incredible 10 years in four weeks… all, apparently, from wearing her makeup to bed.
The experiment was inspired by a recent stat (source unknown) that found a third of women sleep with makeup on at least twice per week. Author Anna wanted to know why, when it’s common knowledge that it’s bad for your skin—so she decided to not wash her face at night for a entire month! Actually, it’s even worse, as she further clarifies:
“I would give my face a cursory wash in the shower each morning but I would be allowed to use none of my usual cleansing creams, and would have to reapply new make-up over the remnants of the old each day.”
I’m not certain, but I think that means she only washed with water… so basically, she didn’t really clean her face AT ALL. Nor did she apply moisturizer. Nor did she exfoliate. (More on those key facts in a second.)
Here’s what Anna looked like before the experiment:
She’s wearing makeup here, so it’s impossible to really assess the true condition of her skin going into this. To me, it looks like she has some minor inflammation (redness), fine lines, sagging and pigmentation.
Here’s what she looked like, with no makeup at all, after the four-week test:
So this is what 10 years older looks like—at least according to the dermatologist in charge of the assessment.
Not good, but in a way there are aspects of her skin that I actually think look better in the “after” picture! Yes, there is a ton of redness and all of those inflamed patches, but I also think her skin has a healthier colour and appears firmer, the pores aren’t so visible and the under-eye area doesn’t look as puffy. Then again, it could just be that I don’t like her makeup job in the “before” photo—that under-eye mascara really drags her face down and I have no idea what’s happening above her eyebrows.
But really, it’s impossible to tell just from photos because the lighting and angles here are not consistent. So I want to examine all of the problems the dermatologist identified after a month of this “routine,” one by one.
Anna’s skin was very flaky and dry by the end of this, particularly on her cheeks, and she had cracking at the corners of her lips. The derm identified a five percent decrease in moisture levels, which resulted in a 10 to 20 percent worsening in skin texture.
Well, duh! She didn’t use moisturizer at all for a month (and I guess no lip balm either), so how is this the left-on makeup’s fault? When women go the occasional night without washing their faces, I guarantee that 99 percent of them are cleansing properly, following with moisturizer, in the morning.
So rather than a study of what happens when you don’t wash off makeup, I think this test is actually reflective of what happens when you don’t moisturize. (To be clear, I’m not saying that everyone needs moisturizer, either—this summer, I’ve been using just my super-light Consonant HydrExtreme serum and my skin has been absolutely fine—but if you have dry skin already, you certainly don’t want to deprive it of something more nourishing.)
Consonant HydrExtreme Extreme Hydration Booster, $149.00
The other thing to mention is exfoliating, which many women do with manual or chemical exfoliants, or just by the act of rubbing with a face cloth or towel after washing. If Anna wasn’t doing this, then it’s no wonder that the dead skin cells built up and contributed to the dryness, along with a duller texture.
Another claim by the dermatologist was that Anna had developed deeper wrinkles, not on her forehead but on the left and right sides of her face. I can’t tell from looking at the pictures, but this is where her skin became driest—so it makes complete sense that the wrinkles would become more visible there too.
The whole moisturizer avoidance thing is a CLASSIC skincare company trick to get you to believe that their products are doing something. Not all of them, but many will run studies where the participants have to avoid moisturizer completely for a week or so before starting the trial of the new product. Obviously there’s going to be an improvement regardless of what fancy ingredients are in it, because moisture plumps up wrinkles. Simple as that.
So again, it’s not the makeup’s fault—just common sense that if you skip a night of moisturizing, then your skin won’t be as plumped-up in the morning.
Anna’s already sensitive skin became two percent more red, which the derm said was a sign of irritation. The makeup forms a barrier over the skin that locks in irritants and keeps out moisture, exacerbating any allergic reactions.
I absolutely agree—although two percent is not very much and this is from an entire month of the behaviour (which is not a realistic way that women care for their skin). Still, I think that us sensitive types need to be very careful whether it’s day OR night. I’ve had allergic reactions develop out of nowhere, even with products I’d been consistently using (like Touche Éclat!), so leaving them on overnight could increase the risk.
The other thing to consider is your eyelashes. Without properly removing her mascara, Anna’s started clumping together, she developed eyelash dandruff and even woke up with a swollen eye one morning (due to a mascara-coated lash getting caught in it). God forbid, you could even develop an eye infection. That alone is enough reason for me to diligently remove my makeup every night!
The best combo I’ve found, that gets absolutely every speck of mascara off, is my no-rinse Bioderma micellar cleanser (in Canada it’s called Sensibio):
With my trusty designer cotton pads:
I was using these products just for removing eye makeup, but that morphed into doing my whole face with them instead of regular cleanser! It works, it’s easy and it feels like less effort than having to splash around in the sink. I don’t think I’ve washed my face at night with gel cleanser for probably four months!
I also really love these:
Yes to Cucumbers Facial Towelettes, $5.99
They’re really gentle and work great at removing even stubborn eye makeup, but won’t dry out your skin.
Anna’s pores became five percent larger, thanks to the build-up of makeup clogging and stretching them, making them more noticeable. The derm said it was a sign that her skin had aged over the month, giving this as the reason:
“Older people naturally have larger pores because, with age, elasticity decreases so the structures that support the skin, and keep pores tight, become slacker.”
Huh? I don’t get how elasticity can be affected in just one month from not washing your face. But still—I am in agreement that leaving on anything that is potentially pore-clogging isn’t the best idea. People with acne-prone skin need to be especially careful about removing all traces of makeup (along with the day’s oil left on skin). Even changing your pillowcases more often can make a difference.
Don’t get me wrong; I’m not advocating sleeping with makeup on by any means. But hey, it happens! And I don’t think it’s the horror show that the Daily Mail is suggesting here–at least not if you’re only doing it on an occasional basis, which I think is how it happens with most of us.
Plus, like I said, most of us double-up on cleansing and moisturizing the day after we sleep with makeup on—not pile more on over top! That’s just not realistic behaviour. I don’t personally know any women who don’t wash their faces or use moisturizer, EVER—but if they’re out there, I’m guessing they probably don’t wear makeup either. So the chance of clogging pores and developing infections and allergies is much less.
As far as aging goes, skipping moisturizer and leaving dry skin to get drier and drier appears to be the worse skin sin than the occasional late night without cleansing.
Let’s talk about this:
Do you ever sleep with makeup on or are you religious about your routine?
What do you make of Anna’s experiment?
Do you think skipping moisturizer is worse than sleeping with makeup on?
The post Will sleeping with makeup on actually age your skin? appeared first on beautyeditor.
HARRISBURG, Pa., Aug. 30, 2013 /PRNewswire-USNewswire/ -- Governor Tom Corbett sent a third letter today to U.S. Department of Health & Human Services Secretary Kathleen Sebelius asking her not to involuntarily move children currently covered under Pennsylvania's Children's Health Insurance Program (PA CHIP) into Medicaid.
The forced move is a requirement of the Affordable Care Act and would be effective Jan. 1, 2014.
Corbett has argued that PA CHIP is a national model that provides not only a robust array of health insurance benefits, but also access to more doctors and hospitals than traditional Medicaid. He's also expressed concerns that moving children from PA CHIP's commercial insurance platform to Medicaid could cause disruptions in their relationships with their health care providers and delays in their ability to access care.
For more information or to read previous correspondence with HHS, visit www.insurance.pa.gov and click on "Affordable Care Act News."
Media contact: Christine Cronkright, Governor's Office, 717-783-1116
Editor's Note: Today's letter is included below. Previous letters on this subject are posted on www.insurance.pa.gov under the "Affordable Care Act News" button.
Aug. 30, 2013
Dear Secretary Sebelius:
As you know, I am very concerned by the U.S. Department of Health and Human Services' (HHS) contention that the Affordable Care Act (ACA) requires certain children in Pennsylvania's Children's Health Insurance Program (PA CHIP) be involuntarily moved into Medicaid.
I communicated this concern to you during our face-to-face meeting on April 2, 2013, in Washington D.C. and in subsequent letters to you dated May 30, 2013, and June 26, 2013. In fact, in all three instances, I specifically asked for approval from the Obama Administration to allow Pennsylvania to preserve PA CHIP for the children and families that currently enjoy its benefits. I have attached copies of those letters that fully explain the Commonwealth's position, why we believe you have the authority to grant this approval and why any ruling to the contrary would directly violate NFIB v. Sebelius.
As a former Governor, you understand the need for timely and definitive answers, yet to date I have not received a response from you to my requests. This prolonged absence of a clear response has created significant operational and systems challenges for Pennsylvania. Any further delays in receiving a response from you only increases the risk of creating additional healthcare disruption for thousands of Pennsylvania children and families.
I ask that you respond in writing to my request by no later than September 6, 2013. I firmly believe that PA CHIP is the right program to meet the healthcare needs of Pennsylvania children. I remain committed to working with you and Pennsylvania families to preserve this great program and ensure all Pennsylvania children have access to quality and affordable healthcare coverage.
Sincerely,
Tom Corbett
Governor
SOURCE Pennsylvania Office of the Governor
RELATED LINKS
http://www.governor.state.pa.us
[product of the day]
Fresh Life Eau de Parfum
$38 USD / $44 CAD for 30mL and $80 USD / $92 CAD for 100mL
Available November 2013 at Sephora
100mL Pre-order now at QVC
Copyright © Beautezine, 2013. | Original Post | No comment | Twitter | Facebook
Categories: Product of the Day
Tags: Fresh, Fresh Life Eau de Parfum
Read the full article.VANCOUVER, August 30, 2013 /PRNewswire/ --
NASDAQ: CRME TSX: COM
Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) ha anunciado hoy que la compañía tendrá un expositor y que patrocinará un simposio satélite en el próximo Congreso ESC 2013 celebrado en Ámsterdam, Países Bajos, del 31 de agosto al 4 de septiembre.
Esta conferencia anual está organizada por la Sociedad Europea de Cardiología y se centra en la ciencia, gestión y prevención de la enfermedad cardiovascular.
"Estamos encantados de poder participar de nuevo en el prestigioso congreso anual de la Sociedad Europea de Cardiología", dijo Karim Lalji, director comercial de Cardiome. "Este es el primero de una serie de encuentros importantes en Europa en el que Cardiome planea participar activamente mientras continuamos para ejecutar la estrategia de comercialización para BRINAVESS".
El simposio satélite, titulado "Recent Advances in the Management of Atrial Fibrillation" se celebrará el sábado, 31 de agosto, de 13.00 a 14.00 en la sala Skopje en el Amsterdam RAI Exhibition and Convention Center. El programa del simposio es el siguiente:
Portavoces: H. Crijns (Maastrict, NL) y J.L. Merino (Madrid, ES)
13:05 - 13:20: D. Atar (Oslo, NO); Las directrices ESC 2012 para la fibrilación atrial
13:20 - 13:35: P. Kirchhof (Birmingham, UK); Aspectos económicos de la fibrilación atrial
13:35 - 13:50: J. Hartikainen (Kuopio, FI); Experiencia en la vida real con vernakalant:
¿ Cuál es el paciente adecuado para este fármaco?
13:50 - 14:00: Conclusión y declaraciones de cierre
Un webcast del simposio estará disponible al público en el sitio web 365 del Congreso ESC (http://congress365.escardio.org/home.aspx) hasta septiembre de 2014.
Acerca de Cardiome Pharma Corp.
Cardiome Pharma Corp. es una compañía biofarmacéutica dedicada al descubrimiento, desarrollo y comercializacion de nuevas terapias que mejorarán la salud de los pacientes en todo el mundo. Cardiome tiene un producto comercializado, BRINAVESS[TM] (vernakalant IV), aprobado en Europa y otros territorios para la rápida conversión de fibrilación atrial de aparición reciente para el ritmo sinusal en adultos.
Cardiome cotiza en NASDAQ Capital Market (CRME) y la Toronto Stock Exchange (COM). Para más información, visite nuestro sitio web en http://www.cardiome.com.
Nota cautelar sobre las declaraciones prospectivas
Determinadas declaraciones de este comunicado contienen declaraciones prospectivas dentro de la Private Securities Litigation Reform Act de 1995 o información prospectiva dentro de la legislación de valores canadiense aplicable que no se basan en hechos históricos, incluyendo, entre otras, declaraciones que contienen las palabras "cree", "podría", "planea", "podrá", "estima", "continúa", "anticipa", "pretende", "espera" y expresiones similares. Las declaraciones prospectivas podrían implicar, entre otros, comentarios con respecto a nuestros objetivos y prioridades para el resto de 2013 y más allá, nuestras estrategias o acciones futuras, nuestros objetivos, expectativas para nuestra condición financiera y los resultados de, o perspectiva para, nuestras operaciones, investigación y desarrollo y desarrollo de productos y fármacos. Dichas declaraciones prospectivas implican riesgos conocidos y desconocidos, incertidumbres y otros factores que podrían causar que los resultados reales, eventos o desarrollos sean materialmente diferentes de los resultados, eventos o desarrollos futuros expresados o implícitos por dichas declaraciones prospectivas. Muchos riesgos conocidos, incertidumbres y otros factores se tienen en cuenta como parte de nuestras suposiciones subyacentes a estas declaraciones prospectivas e incluyen, entre otros, los siguientes: las condiciones económicas y empresariales generales en Estados Unidos, Canadá, Europa y otras regiones en las que operamos; la demanda de mercado; los cambios tecnológicos que podrían afectar a nuestros productos existentes o nuestra capacidad para desarrollar y comercializar productos futuros; la competencia; la legislación gubernamental existente y regulaciones y cambios en, o el fallo al cumplir con, la legislación y regulaciones gubernamentales; la disponibilidad de la cobertura de reembolso financiero de contribuyentes gubernamentales y de terceros para productos y tratamientos relacionados; los resultados negativos o retrasos no esperados en procesos de desarrollo de producto clínicos y preclínicos; los hallazgos negativos relacionados con la seguridad y/o eficacia de nuestros productos o productos; las decisiones, y el momento de las decisiones, hechas por las agencias reguladoras de salud en cuanto a la aprobación de nuestra tecnología y productos; el requisito de financiación para expandir las actividades comerciales; y cualquier otro factor que podría afectar a nuestro rendimiento. Además, nuestro negocio está sujeto a determinados riesgos operativos que podrían causar que cualquier resultado expresado o implícito por las declaraciones prospectivas en esta presentación difiera materialmente de los resultados reales. Estos riesgos operativos incluyen: nuestra capacidad de atraer y retener a personal cualificado; nuestra capacidad de completar con éxito desarrollo clínico y preclínico de nuestros productos; cambios en nuestra estrategia empresarial o planes de desarrollo; cuestiones de propiedad intelectual, incluyendo la inejecución o pérdida de la protección de patente resultante de retos de terceros a nuestras patentes; aceptación de mercado de nuestra tecnología y productos; nuestra capacidad para fabricar, comercializar y vender con éxito nuestros productos; la disponibilidad de capital para financiar nuestras actividades; y cualquier otro factor descrito en detalle en nuestras presentaciones a la Comisión de Bolsa y Valores disponibles en http://www.sec.gov y las autoridades regulatorias de valores canadienses en http://www.sedar.com. Dados estos riesgos, incertidumbres y factores, se recomienda que no deposite una confianza indebida en dichas declaraciones e información prospectiva, que se califican en su totalidad por esta declaración cautelar. Todas las declaraciones e información prospectiva efectuadas aquí se basan en nuestras expectativas actuales y no asumimos ninguna obligación para revisar o actualizar dichas declaraciones prospectivas para reflejar eventos o circunstancias posteriores, excepto que se requiera por ley.
Para más información:
Relaciones de inversor de Cardiome
+1-(604)-676-6993 o llamada gratuita: 1-800-330-9928
E-mail: ir@cardiome.com
SOURCE Cardiome Pharma Corp.
ST. LOUIS, Aug. 29, 2013 /PRNewswire/ -- Nothing puts a damper on end-of-summer picnics and campouts faster than biting bugs. Unfortunately, mosquitoes and other insect pests come with the summertime territory. You can keep pesky – and sometimes dangerous – bugs from ruining your time outdoors over the long Labor Day weekend by taking three steps for complete protection: Treat yourself, treat the yard and treat your deck, patio or campsite. By creating a Bite-Free Zone™ of protection during your festivities, you can help keep your family safe from mosquitoes and the diseases they may carry.
1. First, use a personal insect repellent as your main line of defense against biting bugs. The Centers for Disease Control and Prevention recommends using a repellent when spending time outdoors as a highly effective way to minimize risk of contracting West Nile virus and other mosquito-borne illnesses. Personal repellents are available in a variety of application methods and active ingredients, ranging from the familiar DEET to newer ingredients like oil of lemon eucalyptus.
Did you know that mosquitoes can detect an unprotected area of skin the size of a dime? In addition to using a personal repellent, you can limit your exposure by dressing strategically: Wear long sleeves and long pants outdoors when mosquitoes are most active (around dusk and dawn). Avoid using scented soaps, perfumes and hair spray when you know you're going to be outside for an extended period of time.
2. Second, treat your lawn with an all-purpose, EPA-registered lawn insecticide with residual efficacy against mosquitoes. Cutter® Backyard™ Bug Control Spray Concentrate, for example, creates a barrier against biting bugs in your lawn for up to 8 weeks of control. Spray over the entire yard, including ornamental trees, shrubs and flowers, and onto outdoor surfaces. Just remember to spray early enough to allow the product to completely dry before your Labor Day backyard get-together.
Mosquitoes breed near sources of water. Be proactive in preventing mosquitoes from congregating in your lawn. Remove standing water in flower pots, on pool covers and in outdoor pet bowls. Make sure your gutters are clean and unclogged and that your downspouts drain effectively so puddles aren't left behind after it rains. Mow your lawn regularly to keep mosquitoes from seeking refuge on tall grass.
3. Last, use an area repellent around your patio, deck or campsite to create a zone of mosquito protection while you're spending time outdoors. Easy-to-use, all-weather citronella products, such as the American Holiday-themed Cutter® CitroGuard® Triple Wick Candle, use the natural repelling properties of citronella oil to repel mosquitoes and other flying bugs. If you're camping out or picnicking, bringing along an area fogger such as Cutter® Backyard™ Bug Control Outdoor Fogger can give you several hours of mosquito protection. Just spray infested areas or surfaces and allow the fog to drift over the area.
For more information about West Nile virus and ways to protect against mosquitoes, visit www.cdc.gov/westnile. To learn more about Cutter® products, visit www.cutterinsectrepellent.com.
About United Industries
United Industries Corporation, a Spectrum Brands Company, is the leading manufacturer of value-brand consumer products for the home, lawn and garden insect and weed control markets in the United States. The company offers innovative products of outstanding quality, so consumers benefit from easier insect and weed control solutions. The brands — Spectracide®, Garden Safe®, Hot Shot®, Cutter®, Repel® and Black Flag® — are well recognized by consumers for delivering exceptional value and trusted results. For more information, visit www.UnitedIndustriesCorporation.com.
About Spectrum Brands Holdings, Inc.
Spectrum Brands Holdings (NYSE: SPB), a member of the Russell 2000 Index, is a global and diversified consumer products company and a leading supplier of consumer batteries, residential locksets, residential builders' hardware, faucets, shaving and grooming products, personal care products, small household appliances, specialty pet supplies, lawn and garden and home pest control products, and personal insect repellents. Helping to meet the needs of consumers worldwide, our Company offers a broad portfolio of market-leading, well-known and widely trusted brands including Rayovac®, Kwikset®, Weiser®, Baldwin®, National Hardware®, Pfister™, Remington®, VARTA®, George Foreman®, Black & Decker®, Toastmaster®, Farberware®, Tetra®, Marineland®, Nature's Miracle®, Dingo®, 8-in-1®, FURminator®, Littermaid®, Spectracide®, Cutter®, Repel®, Hot Shot® and Black Flag®. Spectrum Brands' products are sold by the world's top 25 retailers and are available in more than one million stores in approximately 140 countries. Spectrum Brands Holdings generated net sales of approximately $3.25 billion in fiscal 2012. On a pro forma basis following the Company's December 2012 acquisition of the Hardware & Home Improvement Group (HHI) from Stanley Black & Decker, Spectrum Brands had net sales of more than $4 billion for fiscal 2012. For more information, visit www.spectrumbrands.com.
Media contact:
Connie Caldwell, United Industries Corp.
314-683-2460, connie.caldwell@spectrumbrands.com
SOURCE United Industries Corporation
RELATED LINKS
http://www.unitedindustriescorporation.com
Welcome to the cycle of GWODs designed by Kelvin Gary and Katherine Simmons of Body Space Fitness! Note: Exercise descriptions with video links are included below the image.
Have thoughts on the new graphic design of Greatist's Workouts of the Day? Email us at gwod [at] greatist.com!
· Here’s a video demonstrating the squat to press.
· There’s a lot more to bodyweight squats than you think! Learn good squatting form to get those most out of your bodyweight squats.
· Understand the difference between wide grip lat pull-downs and narrow grip lat pulldowns.
Track it on Cody using the #imagreatist hashtag.
WEST HILLS, Calif., Aug. 27, 2013 /PRNewswire/ -- The dentists operating out of West Hills Smiles, a top-notch office specializing in concierge dentistry, are spreading the word about their signature approach to their craft. With two spreads in popular magazines out this month, Ben Reyhani, DDS and Pasha Hakimzadeh, DDS share their feelings on a broad range of topics, from anti-aging tips to restorative dentistry techniques. The full-page layouts also help establish the smile makeover experts as authorities in the field of cosmetic dentistry for style-minded patients.
The first one was published in the September issue of the style bible for many women, Cosmopolitan. Behind the cover graced by Nina Dobrev lies a page on "the Smile of Your Dreams" featuring the beaming faces of Dr. Ben and Dr. Pasha. Here, the pair answers common questions that they've most likely heard from many patients:
The West Hills Smiles resident dentists then explain their smile makeover treatment methods for each of these questions. Whiter teeth, up to 4 shades, can be achieved through "a simple in-office power whitening" followed up with home care, most likely through take-home trays or standard good dental habits. For straighter teeth, the doctors promote their clear braces treatment, which is less invasive than metal brackets and can even be removed for important events. Finally, they describe their complete dental makeover plan in response to the last question, performed by strategic and effective use of porcelain veneers.
The second ad targets a more local niche. Featured in the August issue of Angeleno, the Los Angeles-based title from Modern Luxury, an interview with Dr. Pasha proffers "solutions for an aging face." The spread highlights the dental issues that come with age and their often unattractive impact of maturing a patient's appearance. Changes in smiles as we age, including shorter teeth, altered bite, and loss of tautness of the skin around our mouths, are offered minimally-invasive solutions by Dr. Pasha. Through an approach that differs for each patient and respects their individuality, a West Hills Smiles patient can take years off of his or her appearance. This most commonly means utilizing a combination of veneers, gum reshaping, tooth whitening, replacing metal amalgam fillings with tooth-colored materials, and other cosmetic dental treatments.
To experience dentistry fresh out of the pages of your favorite luxury or fashion magazine, contact the West Hills Smiles team to schedule a consultation with Dr. Ben or Dr. Pasha at your earliest convenience. The doctors always prioritize the comfort of their patients, both in office and through their treatments, prioritizing conservative and preventative methods ahead of invasive surgical means with every single patient. Call West Hills Smiles today at 747-800-4108 or go to www.WestHillsSmiles.com to learn more!
PR Submitted by www.cyberset.com
SOURCE West Hills Smiles
RELATED LINKS
http://www.westhillssmiles.com
Everyone has one. Watching ‘Welcome to the World of Weight Loss’ really bought that home for me. We are so quick to judge, yet have no idea why a person has ended up where they have – be that overweight, an alcoholic, a drug user…
Everyone who attends a weight loss group wants to lose weight! That might sound rather obvious, yet why do some people manage it when others don’t? I don’t think it is a about a lack of desire…I think life gets in the way. Watching WTTWOWL the other evening made me laugh, smile, frown and cry. There were stories about childhood habits, bullying, broken marriages, children with learning disorders with a mum who felt guilty and blamed herself for this, body dismorphic disorder…so many underlying reasons.
I used to think that losing weight was a case of eating less and moving more…and that if you really wanted it, you would do it. If I am being honest, I still do think this to a great extent – but after seeing these stories, and those of people who contact me – I am mellowing a little. This isn’t to make excuses, but just to understand that weight is a complex issue. There are a variety of reasons that got us there, and a variety of reasons that hinder us getting back again!
The programme made me chuckle at times, but I felt so bad for people at the same time. I don’t actually think – as with most weight loss programmes – that it gave a balanced and fair view. For example, Weight Watchers is not a bad plan, yet the list of foods eaten in one day by one lady was horrendous. There were dolly mixtures, spring rolls, crackers and cheese, chicken burger, Danish biscuits, more spring rolls and not a veggie in sight – bless her! She was thrilled that she had been on plan that day though. It is hard not to make comparisons with Slimming World when you see things like this…you just couldn’t eat that in a day. There are good and bad on both plans though!
I listened to the presenter saying that syns were to be used for ‘guilty pleasures’…there is nothing ‘guilty’ about syns. It actually represents the word ‘synergy’ and is the thing that Slimming World believe helps us to stick to the plan and brings it all together. Another TV method of promoting weight loss organisations in a poor light! 
Rosemary Conley is a plan that I don’t know much about – I know what is involved, but I have never tried it…only because there was never a local group though. I liked the portion pots that they hand out, but I wasn’t that keen when the leader – in a ‘private’ discussion with the presenter – said, “because unfortunately fat is not beautiful.” This was in relation to a question she was asked about whether or not she would still love her partner if they put weight on…it was a resounding ‘no!’…shame really; I wonder what her fat clients think after watching that…and whether her partner has stuck around!
I watched Panos – a Greek chap who tried to put on a happy front – talking about how he wasn’t happy to get fat, but was happy eating the food. Then there was Tammy – an emotional eater – who blames herself and carries so much guilt over her daughter who has severe learning difficulties…I cried a little watching her get upset. Hazel – who has body dismorphic disorder – and only leaves the house to attend her Rosemary Conley groups and to go to the shops…but has to be accompanied by her parents; it is too traumatic for her to leave the house. And then there was the lady who felt that God showed her the way to Weight Watchers…by creating a situation where she fell off a bus and had to be picked up by four men. So many sad stories with differing levels of weight loss success – but I doubt that any of us could say that their desire to lose weight was not there.
So just take a moment to think about your story. Would you want someone judging you without them knowing it? Maybe when you are next in class and wondering why that person never seems to lose weight, you could give them a bit of support. Unless of course Pizza Lady turns up at group…if so, just leave her be! 
Right then…the usuals…
Today has been a bit of a nightmare. My story is that I never had any real reason to overeat – I started being a little greedy madam as a child (often behind my parents back – swapping good food for not so good food at school, getting the dinner ladies to give me leftovers!) and then learnt to rely on food for comfort – despite a loving home environment.
My story at the moment is that I am having an identity crisis. I used to be the career girl…the youngest and most successful in the first few companies I worked at – the only one in the family to go to university – a mortgage by the time I was 22 – a Mercedes by the time I was 23 – and TAG watches and expensive handbags (handbags and watches still fit fatties…so no designer label clothes, but plenty of designer accessories!) all paid for with the big income. Now, well now I don’t have that job…and I feel that I have lost my identity really. What is my purpose now? I don’t really want to return to the same sort of job just yet, as I want to keep the focus on hitting my target – and the work I did involved long hours, travel away from home…not exactly conducive to getting to group and getting the exercise in…or keeping the stress levels down. I feel like a bit of a waster – and this isn’t a plea for sympathy, or a call for a symphony of violins – but I feel as if I lack purpose. I know that I have so much to be thankful for, and so I don’t want to sound like a madam, but I have just lost my way a little and I am not at all where I had thought that I would be by the time I was 32. I have a plan of action…but I am having a wibble about it – would I make a good coach, will I get approved as a foster carer, will I ever get to my target…so many questions and so much uncertainty – it can be a bit overwhelming at times. I just need to man up and get on with it though I think!
So that is why today has been a bit of a nightmare…it has all been playing on my mind. And I also woke up with leg strain…pants!
Other than my mind working overdrive, I have worked on my other half’s project, been to the horses and to Asda, seen the kids…and am about to settle down and watch some TV to unwind.
Breakfast: Fruit salad.
Exercise: Nothing today.
Thank you for reading – and have a wonderful weekend!
Weight Loss Bitch xxx
Read the full article.The new Marc Jacobs Beauty cosmetic line includes the Marc Jacobs Beauty Magic Marc’er Precision Pen Eyeliner ($30 USD / $36 CAD), a black, felt-tip liquid eyeliner.. Marc Jacobs Beauty will be available exclusively at Sephora and Marc Jacobs stores on August 9, 2013 and is inspired by the spirit of youth, confidence and experimentation.
I already posted a review of this eyeliner in which I was very disappointed. I definitely received a defective eyeliner, and since I was one of the first to actually try the product, I had no idea that so many people loved this eyeliner (or else I would have assumed sooner). The one I had was defective in that it still worked, so it didn’t seem defective… it just seemed like an awful eyeliner! I have since received a new one, and I’m happy to re-publish this review with my updated thoughts.
This eyeliner comes in a long, sleek black lacquered pen with a felt-tip applicator. It’s a very beautiful, elegant and artistic-looking product. The applicator is quite stiff and comes to an ultra-precise point, which is great for detail work like getting into the inner corner and creating a perfect cat-eye flick. The harder you press, the thicker the line, the lighter you press, the thinner the line- almost like a calligraphy pen. This is where my original eyeliner failed- it applied the eyeliner with a lot of pressure, but not when you used it lightly (therefore it went on super patchy and messy).
The eyeliner formula is very liquidy, although still ultra black and pigmented. It dries fairly quickly, and it’s completely waterproof- there’s no budging this eyeliner until you remove it with an oil-based makeup remover. I’m still playing with it to see if it will replace my beloved Lancôme Artliner- so far, it’s looking pretty good for Marc!
I’m happy to say this eyeliner is a complete dream to work with- and thank you to all of you who suggested I try out another one!
Marc Jacobs Beauty Magic Marc’er Precision Pen Eyeliner, Swatched
[summary]
AVAILABILITY: Permanent. Available now at Sephora.
SELECTION: 1 shades available (‘Blacquer’). See the rest of our Marc Jacobs Beauty coverage here.
Copyright © Beautezine, 2013. | Original Post | 7 comments | Twitter | Facebook
Categories: Reviews
Tags: Eyeliner, Eyes, Liquid Eyeliner, Makeup, Marc Jacobs, Marc Jacobs Beauty, Marc Jacobs Beauty Magic Marc'er Precision Pen Eyeliner
Here is the full post.
Researchers have found that silibinin, an extract from milk thistle, can actually combat skin cancer and photo-aging in two specific ways. According to their work, milk thistle is both able to repair skin cells damaged by radiation and destroy those that may go on to cause cancer.
In regards to UVA radiation, which according to GreenMedInfo, makes up 95% of the radiation reaching earth, silibinin-treated skin cells reacted far better to radiation, with a dramatic number of damaged cells dying off of their own accord. In addition, the silibinin was completely non-toxic to undamaged cells. In other words, the silibinin seemed to intelligently differentiate between damaged and non-damaged skin cells, killing only those that could go on to cause cancer.
The same researchers looked at silibinin and UVB radiation in another study. UVB radiation accounts for 5% of the sun’s radiation reaching Earth. In that study, the silibinin didn’t kill off the cells damaged by UVB radiation, but instead protected them from the DNA damage that could lead to cancer. It repaired them.
Some of their research was recently published in Phytochemistry and Photobiology.
The ways in which nature can almost intelligently act within the body are truly remarkable. In 2007, research published in Integrative Cancer Therapies reviewed numerous clinical studies suggesting milk thistle’s positive effects on cancer. After examination and according to the abstract: “there is strong preclinical evidence for silymarin’s hepatoprotective and anticarcinogenic effects, including inhibition of cancer cell growth in human prostate, skin, breast, and cervical cells”.
Although the research directly on humans has not been carried out, you can find milk thistle in seeds, supplements, and liquid extracts. It can be used for appetite improvement, heartburn, liver disorders, inducing menstruation, increasing lactation, depression, malaria, and even hangovers.
NEW YORK, Aug. 23, 2013 /PRNewswire-USNewswire/ -- In its rush to vindicate Ireland's recent abortion legislation, the Irish Times again misled its readers today by claiming that the nation's "first abortion" had been carried out under the new law.
Information brought forward, however, indicates that this was a medical intervention necessary to save a woman's life, not an abortion. The woman, at risk from sepsis, delivered twin babies who were tragically too young to survive outside the womb.
"As the Irish Times reporter well knows, our most senior obstetricians, such as Dr. Sam Coulter Smith, the Master of the Rotunda, have repeatedly stated that these interventions should not be described as abortions, since the intent is not to kill the baby," said Niamh Uí Bhriain of the Life Institute. The distinction was also highlighted in the guidelines of the Irish Institute for Obstetricians and Gynaecologists. http://www.thelifeinstitute.net/latest-news/false-irish-times-headline-misleads-public-with-first-abortion-claim/
"The claim that such interventions are abortions are hugely upsetting to the mothers and families involved who are already grieving the loss of their babies, and should not be exploited by the Irish Times or abortion campaigners," she said.
Personhood USA supports life-saving medical interventions intended to save both mother and child, even if such interventions risk the life of the unborn child. They point to the Dublin Declaration, which proves it is never medically necessary to intentionally kill an unborn child through abortion. http://www.dublindeclaration.com/
The hospital acknowledged that this kind of intervention would have taken place prior to the legislation, a detail buried in the Irish Times article and not reflected in its sensationalist headline. In fact, the Department of Health confirmed that the abortion legislation has not yet come into effect.
Last November, the Irish Times published the headline "Woman 'denied a termination' dies in hospital." The reporter later admitted that the woman, Savita Halappanavar, did not in fact request an abortion, according to the hospital record. http://www.personhoodusa.com/irish-times-reporter-admits-savita-did-not-request-abortion-according-hospital-record
"Spreading misinformation like this is part of an ongoing betrayal of the Irish people," said Josh Craddock, Personhood USA's United Nations liaison. "The Irish Times has repeatedly exposed their blatant pro-abortion bias by putting their political agenda above honest reporting of the facts."
SOURCE Personhood USA
RELATED LINKS
http://www.personhoodusa.com
